AUTHORS
Chenying Li, PhD, Yinjun Lou, MD2, Liping Mao3, Weiyuan Mai4, Jian Huang, MD, PhD5, Haitao Meng6, Wenjuan Yu7, Xinping Zhou8, Xingnong Ye9, Hongyan Tong, MD, PhD10, Huafeng Wang, MD11, Jie Jin, MD12
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
7 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
9 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
10 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
11 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
12 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
ABSTRACT
Background:
The treatment landscape for Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (Ph-negative B-ALL) has been transformed by the emergence of potent immunotherapeutic agents. Blinatumomab, inotuzumab ozogamicin, and venetoclax have each demonstrated substantial clinical activity, leading to improved outcomes in both relapsed/refractory and frontline settings. While these novel agents offer a promising alternative to traditional cytotoxic regimens, critical questions remain unresolved regarding their optimal integration into frontline therapy—specifically, the most effective sequencing, combination, and duration of these agents, and the extent to which chemotherapy can be safely minimized or eliminated altogether. To address these gaps, we designed a prospective study evaluating a novel, chemotherapy-minimized, sequential strategy comprising venetoclax plus blinatumomab as induction, followed by inotuzumab ozogamicin (VBI-seek regimen) as consolidation, in older adults with newly diagnosed Ph-negative B-ALL. Here we report the efficacy and safety of this immunotherapy-driven approach.
Aims:
We evaluated the efficacy and safety of a novel, chemotherapy-minimal sequential regimen comprising venetoclax plus blinatumomab induction followed by inotuzumab ozogamicin-based consolidation as frontline therapy for older adults with newly diagnosed Ph-negative B-ALL.
Methods:
This prospective, single-center Phase 2 study (NCT06554626) is enrolling adults aged ≥40 years with newly diagnosed Ph-negative B-ALL, with enrollment initiated in August 2024. The VBI-seek regimen comprised 6 cycle of induction and consolidation, followed by cyclical intensified maintenance therapy as long as 2 years. The induction regimen consists of venetoclax administered in a 3-day dose ramp-up (100 mg, 200 mg, and 300 mg on days 1, 2, and 3–28, respectively; plus blinatumomab given 9ug on days 2-8 and 28ug on days 9-15 Patients who achieve response and elect to undergo allogeneic hematopoietic stem cell transplantation or CAR-T cell therapy as consolidation will discontinue protocol treatment. Clinical response was assessed at the end of each cycle, and safety was summarized descriptively. The primary endpoint was 2-year event free survival rate (EFS) . Secondary endpoints included complete remission rate (CR/CRi), overall survival rate (OS), minimal residue disease (MRD) and safety analysis.
Results:
Patient characteristics and enrollment
Twelve patients aged ≥40 years were enrolled and all completed cycle 1 response assessment. The median age was 55 years (range, 40–74), and 66.7% were male. Baseline laboratory values were as follows: median WBC 3.32×10?/L (range, 1.41–28.31), hemoglobin 76 g/L (range, 55–136), platelets 53.5×10?/L (range, 13–210) and LDH 678 U/L (range, 184-2577).
Efficacy outcomes
After cycle 1, the CR/CRi rate was 91.7% (11/12); the sole non-responder had TP53/IKZF1 co-mutations and withdrew. Remission was sustained among evaluable patients through cycle 2 (11/11), cycle 3 (8/8), and cycle 4 to 6 (6/6). Subsequent therapy included allogeneic HSCT (n=1), CAR-T (n=1), and maintenance (n=5). One patient relapsed but achieved remission following 2 weeks of blinatumomab re-induction. With a median follow-up of 8 months, one relapse occurred and no deaths were observed. The estimated 12-month OS and EFS were 100% and 73.3%, respectively.
Safety
Grade 3–4 hematologic toxicities included neutropenia (83.3%), anemia (75.0%), and thrombocytopenia (66.7%); red blood cell and platelet transfusions were required in 7 and 5 patients, respectively. Grade 3–4 non-hematologic toxicities were rare: tumor lysis syndrome (8.3%) and febrile neutropenia (8.3%). Cytokine release syndrome occurred in 11 patients (grade 1, n=10; grade 2, n=1) and resolved with standard management; no ICANS was reported; and no cases of VOD/SOS were observed.
Conclusion:
The VBI-seek sequential regimen represents a paradigm-shifting approach to frontline therapy for older adults with Ph-negative B-ALL, demonstrating that deep and durable molecular remissions can be achieved without intensive cytotoxic chemotherapy.
Keywords: Philadelphia chromosome-negative acute lymphoblastic leukemia | Venetoclax | Blinatumomab | Inotuzumab ozogamicin
DISCLOSURES
Chenying Li, PhD: No relevant conflicts of interest to declare.